Genexine Seeks China Entry Through Multi-Biologic Tasly Tie-Up
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech firm Genexine is broadening its presence in Asia. Following an agreement earlier this month with Kalbe Farma to set up a joint venture in Indonesia, it has now signed a licensing out deal for protein therapies with a subsidiary of China’s Tasly Pharmaceutical.
You may also be interested in...
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum
Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an asset with the Shanghai-based I-Mab Biopharma. The South Korean firm expects the deal to serve as a yardstick of ‘value determination’ in its future global transactions.
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
SillaJen Faces Delisting Despite New Owner's Capital Injection
Oncolytic virus firm SillaJen, which hoped to get back on track and resume stock trading after it found a new owner last year, is set to be delisted from Korea’s Kosdaq market as the exchange makes a preliminary decision.